Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.
CDK inhibitors; Breast cancer; Palbociclib
Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol. 2019;11:1758835919833867.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/4251
The following license files are associated with this item: